andrea
j
pruijsser
mark
r
denison
recent
outbreak
sarscoronaviru
merscoronaviru
cov
heighten
awar
lack
vaccin
antivir
compound
approv
prevent
treatment
human
potenti
zoonot
cov
anticov
drug
develop
long
challeng
activ
proofread
exoribonucleas
uniqu
cov
recent
promis
nucleosid
analogu
broadspectrum
activ
cov
identifi
review
discuss
progress
made
develop
antivir
nucleosid
nucleotid
analogu
target
viral
rna
synthesi
effect
therapeut
cov
infect
propos
promis
strategi
combin
therapi
coronavirus
cov
famili
envelop
virus
contain
positivesens
rna
genom
cov
belong
famili
coronavirida
within
order
nidoviral
coronavirida
henceforth
refer
cov
infect
broad
rang
vertebr
includ
mammal
bird
six
cov
strain
isol
human
four
strain
caus
usual
mild
selflimit
upper
respiratori
infect
account
estim
common
cold
two
human
cov
strain
produc
seriou
respiratori
diseas
epidem
recent
year
sever
acut
respiratori
syndrom
sar
cov
origin
china
spread
total
countri
caus
case
sar
estim
fatal
rate
caus
ongo
epidem
middl
east
respiratori
syndrom
merscov
first
identifi
saudi
arabia
date
caus
case
countri
fatal
rate
use
human
host
cell
receptor
human
bat
cov
support
predict
signific
risk
emerg
new
potenti
pandem
zoonot
cov
notabl
vaccin
antivir
compound
approv
prevent
treatment
human
potenti
zoonot
cov
emerg
cov
accord
prioriti
statu
govern
agenc
develop
prevent
treatment
strategi
due
sever
infect
credibl
pandem
potenti
review
focu
opportun
challeng
develop
antivir
nucleosid
nucleotid
analogu
target
viral
rna
synthesi
effect
therapeut
cov
infect
drug
current
investig
use
cov
diseas
includ
monoclon
antibodi
directact
antivir
daa
includ
proteas
helicas
polymeras
inhibitor
immunomodul
interferon
corticosteroid
challeng
cov
antivir
develop
gener
rna
virus
specif
cov
replic
positivesens
rna
viru
genom
gener
character
high
error
rate
high
viral
yield
short
replic
time
abund
homolog
nonhomolog
recombin
consequ
viral
swarm
gener
consist
divers
popul
genom
mutant
vari
degre
fit
genet
plastic
challeng
develop
broadli
use
antivir
enabl
rapid
develop
drug
resist
preserv
overal
viral
fit
develop
nucleosid
analogu
inhibitor
cov
hamper
novel
rnadepend
rna
proofread
activ
cov
nonstructur
protein
exoribonucleas
confer
increas
replic
fidel
compar
rna
virus
activ
respons
nativ
cov
high
resist
mani
nucleosid
analogu
includ
ribavirin
nevertheless
recent
develop
nucleotid
nucleosid
analogu
inhibitor
high
barrier
resist
broadspectrum
activ
multipl
cov
abil
inhibit
wt
cov
presenc
hold
promis
treatment
cov
diseas
nucleotid
nucleosid
analogu
inhibitor
hereaft
abbrevi
ni
chemic
synthes
analogu
purin
pyrimidin
heterocycl
ring
sugar
moieti
alter
current
use
treat
chronic
acut
viral
infect
ni
administ
nucleotid
nucleosid
precursor
prodrug
metabol
host
viral
kinas
activ
triphosph
insid
cell
ni
exert
inhibitori
effect
viral
replic
one
nonmutu
exclus
mechan
figur
first
misincorpor
foreign
nucleotid
replic
viral
genom
may
caus
chain
termin
disrupt
subsequ
replic
transcript
chain
termin
may
immedi
oblig
may
occur
follow
limit
extent
continu
rna
dna
synthesi
nonoblig
second
ni
may
incorpor
elong
nucleotid
chain
mispair
andor
substitut
natur
nucleotid
therebi
introduc
mutat
potenti
impair
rna
synthesi
structur
rnaprotein
interact
protein
function
accumul
mutat
loss
viru
viabil
refer
lethal
mutagenesi
error
catastroph
mechan
ni
alter
genet
makeup
viru
lead
decreas
viral
fit
everi
consecut
replic
cycl
final
ni
may
caus
deplet
pool
natur
occur
nucleotid
mimick
ni
demonstr
rel
high
barrier
resist
emerg
structur
conserv
bind
site
polymeras
target
high
among
viru
famili
resist
mutat
gener
incur
fit
cost
enzym
viru
cov
amino
acid
conserv
viral
rdrp
rang
near
maintain
across
genera
suggest
ni
could
potenti
serv
broadspectrum
inhibitor
cov
infect
howev
proofread
activ
activ
protect
cov
mani
ni
effect
rna
virus
effect
inhibit
cov
ni
need
either
evad
recognit
antivir
strategi
mechan
inhibit
nucleosid
nucleotid
analogu
schemat
represent
illustr
normal
replic
rdrp
blue
sphere
prematur
chain
termin
caus
oblig
chain
termin
reduc
replic
fidel
due
mutagen
incorpor
deplet
pool
natur
occur
nucleotid
exon
undergo
uptak
elong
strand
rate
exceed
exon
excis
kinet
next
discuss
sever
antivir
ni
describ
literatur
evid
support
efficaci
cov
ribavirin
guanosin
analogu
broadspectrum
antivir
activ
rna
virus
use
treat
hepat
c
e
viru
respiratori
syncyti
viru
lassa
viru
hantaviru
infect
monophosph
form
ribavirin
interact
inosin
monophosph
dehydrogenas
impdh
host
enzym
vital
nucleotid
biosynthesi
result
decreas
guanosin
product
lead
inhibit
viral
rna
synthesi
though
deplet
cellular
gtp
pool
furthermor
incorpor
triphosph
form
viral
polymeras
lead
lethal
mutagenesi
proofread
activ
exon
leav
cov
impervi
dose
ribavirin
inhibit
virus
effect
although
high
dose
ribavirin
show
partial
inhibit
sarscov
merscov
replic
vitro
tabl
drug
treatment
increas
viral
load
exacerb
diseas
mous
model
sarscov
diseas
ribavirin
treatment
improv
clinic
outcom
sarscov
diseas
human
subject
caus
signific
toxic
synergist
activ
merscov
ribavirin
combin
observ
vitro
rhesu
macaqu
suggest
ifn
increas
potenc
ribavirin
lower
toler
concentr
howev
five
critic
ill
merscovposit
patient
treat
combin
ribavirin
show
clinic
improv
treatment
mer
patient
combin
ribavirin
show
significantli
improv
surviv
day
day
wherea
treatment
mer
patient
combin
ribavirin
yield
surviv
benefit
anoth
studi
thu
although
ribavirin
show
efficaci
vitro
provid
clinic
benefit
human
sarscov
merscov
infect
remdesivir
gilead
scienc
gs
phosphoramid
prodrug
adenosin
ni
effect
filovirus
pneumovirus
paramyxovirus
current
phase
doseescal
trial
ebola
viru
infect
biochem
studi
indic
remdesivir
act
nonoblig
chain
termin
remdesivir
effect
broad
spectrum
human
preepidem
zoonot
cov
potent
inhibit
replic
sarscov
merscov
primari
human
airway
epitheli
cultur
tabl
mice
infect
lethal
dose
sarscov
display
less
weight
loss
lower
lung
viral
titer
reduc
lung
patholog
follow
prophylact
therapeut
administr
remdesivir
partial
resist
phenotyp
attribut
two
mutat
viral
rdrp
suggest
remdesivir
act
target
importantli
fit
virul
remdesivirresist
sarscov
reduc
compar
wt
sarscov
indic
barrier
remdesivir
resist
high
increas
potenc
remdesivir
cov
lack
exon
catalyt
activ
suggest
drug
sensit
proofread
exon
albeit
markedli
lower
extent
ni
rais
import
question
mechan
cov
inhibit
remdesivir
may
recogn
exon
remov
less
effici
may
less
visibl
exon
compar
ni
studi
probe
interact
remdesivir
cov
replic
machineri
like
yield
crucial
insight
ni
circumv
overcom
cov
proofread
activ
turn
appli
model
develop
new
ni
enhanc
potenc
exist
ni
nhc
nhc
cytidin
analogu
demonstr
potent
broadspectrum
antivir
activ
venezuelan
equin
enceph
viru
veev
respiratori
syncyti
viru
rsv
influenza
viru
iav
influenza
b
viru
ibv
chikungunya
viru
chikv
cov
tabl
nhc
exert
antivir
effect
primarili
mutagenesi
viral
rna
serial
passag
presenc
nhc
led
low
level
resist
veev
rsv
iav
bovin
viral
diarrhea
viru
thu
indic
high
resist
barrier
potent
anticov
activ
nhc
demonstr
sarscov
although
mechan
cov
inhibit
determin
micromolarrang
ec
suggest
like
remdesivir
nhc
may
also
novel
way
interact
cov
replicas
coronaviru
antivir
nucleosid
analogu
pruijsser
denison
tabl
nucleosid
analogu
demonstr
activ
human
cov
potent
broadspectrum
antivir
activ
exhibit
nhc
warrant
investig
use
nhc
treatment
cov
infect
either
alon
combin
daa
immunomodul
ni
vitro
activ
cov
low
cytotox
includ
adenosin
analogu
broad
spectrum
activ
posit
neg
sens
rna
virus
shown
antivir
activ
merscov
sarscov
deoxycytidin
analogu
gemcitabin
hydrochlorid
chemotherapi
drug
inhibit
sarscov
merscov
uridin
analogu
activ
immunosuppress
imidazol
nucleosid
mizoribin
inhibit
sarscov
tabl
flexbas
modif
guanosin
analog
acyclovir
acyclovir
flexim
yield
activ
merscov
tabl
research
efficaci
potenc
mechan
cov
inhibit
necessari
determin
whether
develop
compound
cov
antivir
warrant
sarscov
merscov
new
zoonot
cov
like
emerg
diverg
viru
pool
anim
reservoir
therefor
critic
develop
broadspectrum
anticov
strategi
aim
multipl
conserv
target
function
despit
high
conserv
viral
rdrp
low
toler
mutat
key
residu
resist
ni
due
mutat
viral
rdrp
observ
cov
rna
virus
treatment
combin
potent
anticov
ni
could
increas
barrier
resist
enhanc
efficaci
especi
addit
synergist
interact
occur
moreov
therapeut
regimen
combin
drug
distinct
mode
action
interfer
differ
step
viral
replic
cycl
could
simultan
increas
antivir
potenc
broaden
activ
spectrum
reduc
emerg
drug
resist
cov
class
candid
companion
compound
includ
ni
helicas
inhibitor
proteas
inhibitor
monoclon
antibodi
viral
entri
inhibitor
deddh
famili
exoribonucleas
inhibitor
potenti
activ
exon
latter
deserv
special
interest
deddh
inhibitor
aurintricarboxyl
acid
pontacyl
violet
effect
inhibit
lassa
viru
np
exonucleas
proofofconcept
biochem
assay
structur
function
conserv
across
cov
famili
member
absenc
redund
function
elsewher
genom
make
exon
potenti
achil
heel
combin
compound
inhibit
exon
activ
one
ni
would
simultan
reduc
cov
replic
fidel
boost
potenc
ni
mitig
select
pressur
lead
drug
resist
ultim
attenu
viral
diseas
final
sarscov
merscov
infect
spur
exuber
host
inflammatori
respons
rapidli
progress
toward
sever
immunopatholog
probabl
driver
morbid
death
rather
direct
viral
damag
pulmonari
tissu
potenti
limit
therapeut
window
daa
thu
combin
daa
target
immunomodul
may
necessari
halt
lethal
progress
immunopatholog
extend
therapeut
window
intervent
multicent
placebocontrol
doubleblind
random
trial
miracl
current
progress
determin
efficaci
combin
immunomodul
lopinavirritonavir
proteas
inhibitor
cocktail
use
treat
hiv
also
inhibit
merscov
vitro
adequ
control
prospect
studi
like
miracl
urgent
need
assess
efficaci
candid
cov
drug
studi
includ
compound
demonstr
broadspectrum
vivo
efficaci
cov
remdesivir
know
addit
novel
zoonot
cov
inevit
futur
occurr
noth
declar
